Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Aug;6(8):532-42.
doi: 10.1038/nrcardio.2009.105. Epub 2009 Jun 30.

Gender differences in the cardiovascular effect of sex hormones

Affiliations
Review

Gender differences in the cardiovascular effect of sex hormones

Cristiana Vitale et al. Nat Rev Cardiol. 2009 Aug.

Abstract

The higher incidence of cardiovascular disease in men than in women of similar age, and the menopause-associated increase in cardiovascular disease in women, has led to speculation that gender-related differences in sex hormones have a key role in the development and evolution of cardiovascular disease. Compelling data have indicated that sex differences in vascular biology are determined not only by gender-related differences in sex steroid levels, but also by gender-specific tissue and cellular differences that mediate sex-specific responses. In this Review, we describe the sex-specific effects of estrogen and testosterone on cardiovascular risk, direct vascular effects of these sex hormones, and how these effects influence development of atherosclerosis. Cardiovascular effects of exogenous hormone administration are also discussed. Importantly, evidence has indicated that estrogens alone or in combination with progestins in postmenopausal women increase cardiovascular risk if started late after menopause, but that it possibly has beneficial cardiovascular effects in younger postmenopausal women, although data on long-term testosterone therapy are lacking. Hormone therapy should not be considered solely for primary prevention or treatment of cardiovascular disease at this time.

PubMed Disclaimer

References

    1. Int J Obes Relat Metab Disord. 1992 Dec;16(12):991-7 - PubMed
    1. J Clin Endocrinol Metab. 1997 Feb;82(2):682-5 - PubMed
    1. Am J Epidemiol. 2003 Jan 1;157(1):25-31 - PubMed
    1. Lancet. 2007 Aug 25;370(9588):685-97 - PubMed
    1. Climacteric. 2003 Oct;6 Suppl 3:21-8 - PubMed

Publication types